传奇生物Legend Biotech（LEGN）2025年20-F年度报告「NASDAQ」（英文版）（720页）.pdf

1、Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 20-FREGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIES EXCHANGE ACT OF 1934ORANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended Decem

2、ber 31,2025ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from toORSHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934Date of event requiring this shell company reportCommission file number:001

3、-39307LEGEND BIOTECH CORPORATION(Exact name of Registrant as specified in its charter)N/A(Translation of Registrants name into English)Cayman Islands(Jurisdiction of incorporation or organization)Legend Biotech Corporation2101 Cottontail LaneSomerset,NJ 08873(Address of principal executive offices)Y

4、ing Huang,Ph.D.Chief Executive OfficerLegend Biotech Corporation2101 Cottontail LaneSomerset,NJ 08873Telephone:(737)317-5050(Name,telephone,email and/or facsimile number and address of Company contact person)Securities registered or to be registered pursuant to Section 12(b)of the Act:Title of each

5、classTrading Symbol(s)Name of each exchange on which registeredAmerican depositary shares,each representing two ordinary shares,par value$0.0001 per shareLEGNNasdaq Global Select MarketOrdinary shares,par value$0.0001 per share*Nasdaq Global Select Market*Not for trading,but only in connection with

6、the registration of the American depositary shares.Securities registered or to be registered pursuant to Section 12(g)of the Act:None(Title of Class)Securities for which there is a reporting obligation pursuant to Section 15(d)of the Act:None(Title of Class)Indicate the number of outstanding shares